Paradigm Biopharmaceuticals Limited (ASX:PAR – Get Free Report) insider Paul Rennie acquired 95,300 shares of the business’s stock in a transaction that occurred on Tuesday, October 15th. The shares were purchased at an average price of A$0.21 ($0.14) per share, with a total value of A$20,108.30 ($13,405.53).
Paradigm Biopharmaceuticals Stock Performance
The company has a current ratio of 7.22, a quick ratio of 5.93 and a debt-to-equity ratio of 1.00.
About Paradigm Biopharmaceuticals
Featured Stories
- Five stocks we like better than Paradigm Biopharmaceuticals
- What is a Low P/E Ratio and What Does it Tell Investors?
- Analysts Predict New Highs for Cybersecurity Stock by Christmas
- 3 Warren Buffett Stocks to Buy Now
- Nuclear Power Reaches Critical Mass: Top Stocks to Watch Now
- Bank Stocks – Best Bank Stocks to Invest In
- 2 Energy Stocks Surging on Billion-Dollar DOE Loan Commitments
Receive News & Ratings for Paradigm Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paradigm Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.